Abstract
N-linked glycosylation of proteins has both functional and structural significance. Importantly, the glycan structure of a therapeutic protein influences its efficacy, pharmacokinetics, pharmacodynamics and immunogenicity. In this work, we developed glycosylation flux analysis (GFA) for predicting intracellular production and consumption rates (fluxes) of glycoforms, and applied this method to CHO fed-batch monoclonal antibody (mAb) production using two different media compositions, with and without additional manganese feeding. The GFA is based on a constraint-based modelling of the glycosylation network, employing a pseudo steady state assumption. While the glycosylation fluxes in the network are balanced at each time point, the GFA allows the fluxes to vary with time by way of two scaling factors: (1) an enzyme-specific factor that captures the temporal changes among glycosylation reactions catalyzed by the same enzyme, and (2) the cell specific productivity factor that accounts for the dynamic changes in the mAb production rate. The GFA of the CHO fed-batch cultivations showed that regardless of the media composition, the fluxes of galactosylation decreased with the cultivation time in comparison to the other glycosylation reactions. Furthermore, the GFA showed that the addition of Mn, a cofactor of galactosyltransferase, has the effect of increasing the galactosylation fluxes but only during the beginning of the cultivation period. The results thus demonstrated the power of the GFA in delineating the dynamic alterations of the glycosylation fluxes by local (enzyme-specific) and global (cell specific productivity) factors.
Symbols
- α
- Enzyme specific factor
- β
- Specific productivity
- c
- Concentration
- cE
- Extracellular concentration
- f
- Fraction
- K
- Number of time points
- m
- Number of glycoforms
- MW
- Molecular weight
- n
- Number of reactions
- S
- Stoichiometric matrix
- T
- Titer
- t
- Time
- V
- Volume
- VE
- Secretion flux
- VI
- Intracellular flux
- VrefI
- Reference fluxX
- Xv
- Viable cell density
Abbreviations
- CBM
- Constraint-based modelling
- CHO
- Chinese hamster ovarian
- ER
- Endoplasmic reticulum
- FBA
- Flux balance analysis
- GFA
- Glycosylation flux analysis
- IgG
- Immunoglobulin G
- MFA
- Metabolic flux analysis
- PAT
- Process analytical technology
- QbD
- Quality by design
- UPLC
- Ultra performance liquid chromatography
Glycosylation nomenclature
- Man
- Mannosidase
- GnT
- N-Acetylglucosaminyltransferase
- FucT
- Fucosyltransferase
- GalT
- Galactosyltransferase
- SiaT
- Sialyltransferase
- M9
- Man9GlcNAc2
- M8
- Man8GlcNAc2
- M7
- Man7GlcNAc2
- M6
- Man6GlcNAc2
- M5
- Man5GlcNAc2
- A1
- GlcNAcMan3GlcNAc2
- A2
- GlcNAc2Man3GlcNAc2
- FA1
- GlcNAcMan3GlcNAc2Fuc
- FA2
- GlcNAc2Man3GlcNAc2Fuc
- FA1G1
- GalGlcNAcMan3GlcNAc2Fuc
- FA2G1-1
- α(1-6)GalGlcNAc2Man3GlcNAc2Fuc
- FA2G2S1-2
- α(1 -3)GalGlcNAc2Man3GlcNAc2Fuc
- FA2G2
- Gal2GlcNAc2Man3GlcNAc2Fuc
- FA2G2S1-1
- α(1 -6)SiaGal2GlcNAc2Man3GlcNAc2Fuc
- FA2G2S1-2
- α(1-3)SiaGal2GlcNAc2Man3GlcNAc2Fuc